ProCE Banner Activity

My Take on Emerging Agents Targeting HER2, HER3, and TROP2 in NSCLC

Clinical Thought
How could emerging therapies targeting HER2, HER3, and TROP2 affect management of patients with NSCLC? Here are my thoughts on promising agents and potential clinical implications.

Released: November 23, 2020

Expiration: November 22, 2021

Share

Faculty

Sandip P. Patel

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Sandip P. Patel, MD

Professor, Medical Oncology, UC San Diego
Leader, Experimental Therapeutics
Deputy Director, Sanford Stem Cell Clinical Center
Co-Leader, Solid Tumor Therapeutics Program
Medical Director, Clinical Research Informatics
La Jolla, California

Sandip P. Patel, MD, has disclosed that he has received funds for research support from AstraZeneca, Bristol-Myers Squibb, and Merck and consulting fees from AstraZeneca, Bristol-Myers Squibb, Guardant, Illumina, Lilly, Nektar, and Tempus.